News , Products

FDA recommends drug option amid Percorten-V shortage

Dechra’s Zycortal Suspension can be used in place of the Elanco medication.

FDA recommends drug option amid Percorten-V shortage
Percorten-V and Zycortal Suspension are approved for the treatment of canine Addison’s Disease. Standard poodles are among the canine breeds at higher risk of developing the disease.
  • 4
    Shares

The U.S. Food and Drug Administration’s Center for Veterinary Medicine is recommending that veterinarians faced with a shortage of the canine Addison’s Disease drug Percorten-V consider using Zycortal Suspension instead.

Elanco Animal Health, the maker of Percorten-V (desoxycorticosterone pivalate injectable suspension), reported an unspecified problem involving a contract manufacturer.

“While we work diligently to resolve this delay, there is an interruption of product supply to veterinarians,” Elanco stated on the Percorten-V website. “The technical challenges in the manufacturing process are being actively investigated with a focus on expediting resolution. The timeframe to resume production is dependent on the investigation conclusions and at this point is unknown.

“All product that is currently in veterinary clinics is safe to use and meets Elanco’s rigorous quality standards.”

The alternative treatment option, Zycortal Suspension (desoxycorticosterone pivalate injectable suspension), is made by Dechra Veterinary Products.

Both drugs are approved for use as replacement therapies for mineralocorticoid deficit in dogs with primary adrenocortical insufficiency, also known as Addison’s Disease.

MENU